snta

[axelvento]

-70%

.61

 

[axelvento]

up..

.565

 

[axelvento]

down

.55

 

[bemberege]

la seguo pure io per ora la guardo e basta...Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer tiene la cassa piena ma sinceramente non so dove potrebbe arrivare ...

 

[axelvento]

siamo appena appena sopra

.738
chiuso!

si rischia

 

[coffeman]

up da seguire.

 

[playars]

questa stampa
.19 pazzia


SNTA..undiscovered and undervalued 55M low float NASDAQ biotech stock. Malignant mesothelioma (lung cancer) drug phase 1/2 trial results due this month..3 years in progress.

https://clinicaltrials.gov/ct2/show/NCT01590160

137M O/S..

49.2% institutional ownership. Huge institution names own SNTA including:

Morgan Stanley
Goldman Sachs
BNP ParisBas
Charles Schwab
BlackRock
Deutsche Bank
Wells Fargo
Credit Suisse
CitiGroup
Royal Bank of Canada
Vanguard Group
Caxton Corp
Jacobs Levy
Barclays PLC
Swiss National Bank
Panagora
Nomura Holdings

...and more.

Synta Pharmaceuticals Corp. (SNTA) Institutional Ownership & Holdings - NASDAQ.com

-Directors own 11% of the O/S (14M)

-Leaves FLOAT of just 55M

-Significant cash reserves and extensive pipeline of cancer drugs in clinical trials:

Breast Cancer
Acute Myeloid Leukemia
Ovarian Cancer
Colon/Rectal Cancer
Malignant Peripheral Nerve Sheath Tumors
Mesothelioma
Multiple Myeloma
Ocular Melanoma
Small Cell Lung Cancer
Solid Tumors

Synta Pharmaceuticals Corp : Clinical Trials